Actionable news
All posts from Actionable news
Actionable news in MRK: MERCK & CO. Inc,

Will Merck (MRK) Stock Be Hurt by Discontinuing Osteoporosis Drug Development?

NEW YORK (TheStreet) -- Merck (MRK) said it will discontinue the development of its osteoporosis drug odanacatib and will not seek regulatory approval for its use.

The decision follows an independent review of the treatment that confirmed a heightened risk of stroke, the Kenilworth, NJ-based pharmaceutical company said in a statement.

"We are disappointed that the overall benefit-risk profile for odanacatib does not support filing or further development," Roger Perlmutter, president of Merck Research...